Overview

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

Status:
Completed
Trial end date:
2021-08-10
Target enrollment:
Participant gender:
Summary
Double-blind, placebo-controlled, single ascending and multiple dose study. Approximately 32 healthy adult male and female subjects will be given a single capsule of MYMD1 to determine its safety, tolerability, and pharmacokinetic properties. The study data will guide the establishment of an optimum therapeutic dose.
Phase:
Phase 1
Details
Lead Sponsor:
MyMD Pharmaceuticals, Inc.